Article
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
Journal of cancer research and clinical oncology - 19 Feb 2024
Niu Lishui, Wu Honghua, Gao Ruihuan, Chen Liu, Wang Jiangtao, Duan Hexin, Long Yujiao, Xie Yi, Zhou Qin, Zhou Rongrong
Abstract excerpt
BACKGROUND: The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can penetrate blood-brain barrier and are effective for brain metastases (BMs). There is no consensus on the optimal sequence of local therapy (LT) and EGFR-TKIs for symptomatic BM patients because patients suffering neurological symptoms were not enrolled in most clinical trials. METHODS: Non-small cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
